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SHORT REPORT
Dysregulation of lysosomal morphology by pathogenic LRRK2 is
corrected by TPC2 inhibition
Leanne N. Hockey1,*, Bethan S. Kilpatrick1,*, Emily R. Eden2, Yaping Lin-Moshier3, G. Cristina Brailoiu4,
Eugen Brailoiu5, Clare E. Futter2, Anthony H. Schapira6, Jonathan S. Marchant3 and Sandip Patel1,`
ABSTRACT
Two-pore channels (TPCs) are endolysosomal ion channels
implicated in Ca2+ signalling from acidic organelles. The relevance
of these ubiquitous proteins for human disease, however, is unclear.
Here, we report that lysosomes are enlarged and aggregated in
fibroblasts from Parkinson disease patients with the common
G2019S mutation in LRRK2. Defects were corrected by molecular
silencing of TPC2, pharmacological inhibition of TPC regulators
[Rab7, NAADP and PtdIns(3,5)P2] and buffering local Ca
2+
increases. NAADP-evoked Ca2+ signals were exaggerated in
diseased cells. TPC2 is thus a potential drug target within a
pathogenic LRRK2 cascade that disrupts Ca2+-dependent
trafficking in Parkinson disease.
KEY WORDS: Ca2+, LRRK2, Lysosomes, NAADP, Parkinson
disease, TPCN2
INTRODUCTION
Two-pore channels (TPCs) are ubiquitous endolysosomal ion
channels that mediate Ca2+ signals in response to the Ca2+
mobilising messenger nicotinic acid adenine dinucleotide
phosphate (NAADP) (Brailoiu et al., 2009; Calcraft et al.,
2009; Hooper and Patel, 2012). The human isoforms, TPC1 and
TPC2, target to discrete populations of acidic vesicles that
comprise the endolysosomal system (Brailoiu et al., 2009;
Brailoiu et al., 2010; Calcraft et al., 2009). These highly
dynamic organelles undergo continual homo- and hetero-typic
fusion in a Ca2+-dependent manner (Luzio et al., 2007). Fusion
of lysosomes with endosomes or autophagosomes is crucial
for endocytosis and autophagy. Proper functioning of lysosomes
is also dictated by their number (Sardiello et al., 2009) and
position (Korolchuk et al., 2011) within the cell. Lysosomal
morphology might therefore serve as a sensitive read-out of
endocytic well-being. Because TPCs regulate trafficking events
within the endolysosomal system (Grimm et al., 2014; Lin-Moshier
et al., 2014; Ruas et al., 2010; Ruas et al., 2014) there is the
possibility that aberrant TPC activity could underlie endocytic
dysfunction.
Parkinson disease is a progressive neurodegenerative disorder
involving a complex aetiopathogenesis that includes several
genetic causes and risk factors (Hardy, 2010; Schapira and
Jenner, 2011). Mutations in LRRK2 (also known as PARK8) are a
cause of autosomal dominant familial Parkinson disease that is
indistinguishable from sporadic forms (Healy et al., 2008; Paisa´n-
Ruı´z et al., 2004; Zimprich et al., 2004). LRRK2 is a large
modular protein comprising both enzymatic domains (a ROC
and kinase domain) and domains involved in protein–protein
interactions (Cookson, 2010). The function of LRRK2 is not
clear, but LRRK2 localises, at least in part, to the endolysosomal
system (Alegre-Abarrategui et al., 2009; Biskup et al., 2006), and
a number of studies (albeit using recombinant systems and animal
models) implicate LRRK2 in endolysosomal trafficking and
associated processes such as endocytosis and autophagy (Dodson
et al., 2012; Go´mez-Suaga et al., 2012; MacLeod et al., 2013;
Shin et al., 2008).
Here, we examined endolysosomal morphology in fibroblasts
from Parkinson disease patients with the common LRRK2
G2019S mutation. We identify pronounced lysosomal morphology
defects, which were reversed by inhibition of TPC2 and associated
regulators. Our data thus suggest that TPC2 acts downstream of
pathogenic LRRK2 to regulate trafficking within the endolysosomal
system in a pathway of potential relevance to the pathology of
LRRK2-mediated Parkinson disease.
RESULTS AND DISCUSSION
Lysosomal morphology is disrupted in LRRK2 G2019S
patient fibroblasts
We examined the morphology of lysosomes in primary cultured
fibroblasts from LRRK2 G2019S Parkinson disease patients
(LRRK2-PD cells) using three independent methods. In the
first analyses, we stained live cells with the fluorescent
acidotrope, LysotrackerH. This probe can be used to infer
lysosome volume, which has recently been validated as a novel
biomarker for lysosomal storage disorders (te Vruchte et al.,
2014). In healthy control fibroblasts, lysosomes were well
resolved as puncta (Fig. 1A). In contrast, lysosomes appeared
enlarged and clustered in age-matched LRRK2-PD fibroblasts
(Fig. 1B).
In a second approach, we assessed lysosomal morphology in
fixed cells by immunocytochemistry using a primary antibody
raised to the late endosome and lysosome marker LAMP1. Again,
lysosomes were enlarged in the patient fibroblasts (Fig. 1D)
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compared to controls (Fig. 1C). This defect was manifest as an
approximate doubling in intensity of LAMP1 labelling in
LRRK2-PD cells (Fig. 1E). We also noted a propensity of
lysosomes to cluster close to the nucleus in the patient fibroblasts
(Fig. 1D,E). Similar defects were obtained using cultures derived
from three other patients when compared to healthy controls
(supplementary material Fig. S1) although western blot analysis
did not reveal any consistent change in total LAMP1 levels
(supplementary material Fig. S2A).
In the final approach, we performed electron microscopy to
resolve the morphology of individual lysosomes. An example of a
lysosome from a healthy control fibroblast displaying the typical
electron dense interior is shown in Fig. 1F. Lysosomes in fibroblasts
from Parkinson disease patients were more heterogeneous, and were
often swollen and characterised by large translucent areas (Fig. 1F).
Quantification of lysosomes in random sections showed that the
average area was increased approximately sixfold whereas density
was decreased approximately threefold (Fig. 1G).
The G2019S mutation in LRRK2 falls within its kinase domain
and is associated with increased kinase activity (West et al.,
2005). We therefore examined the effect of LRRK2-In1, a
recently described potent LRRK2 kinase inhibitor (Deng et al.,
2011). As shown in Fig. 1H, lysosomal morphology in LRRK2-
PD fibroblasts reverted to a normal appearance following a 3-
day treatment with LRRK2-In1 (100 nM). Similar results were
obtained upon shorter treatments (supplementary material Fig.
S3). We also tested a structurally distinct LRRK2 kinase
inhibitor, GSK2578215A (Reith et al., 2012). GSK2578215A
(32 nM) also normalised lysosomal morphology in LRRK2-PD
cells (Fig. 1I). Pooled data are presented in Fig. 1J. Taken
together, we identified pronounced changes in lysosomal
morphology in fibroblasts from LRRK2-associated Parkinson
disease patients that are dependent on LRRK2 kinase activity.
Lysosomal defects are reversed by silencing TPC2 but
not TPC1
The observed changes in lysosomal morphology in LRRK2-PD
fibroblasts described here are reminiscent of those recently
described upon overexpression of TPC2 (Lin-Moshier et al.,
2014). To probe the role of TPCs in LRRK2 action, we used
small interfering RNAs (siRNAs) to silence TPC expression in
LRRK2-PD fibroblasts. As shown in Fig. 2A–C, lysosomal
Fig. 1. Pathogenic LRRK2 disrupts
lysosomal morphology in a kinase-
dependent manner. (A,B) Confocal
images of LysotrackerH red fluorescence
in live fibroblasts derived from a healthy
control (A) and a Parkinson disease (PD)
patient harbouring the LRRK2 G2019S
mutation (B). Higher magnification images
are shown in the right panels. Scale bars:
5 mm (and also apply to B–D,H,I).
Fluorescence intensity was increased
1.460.07-fold (mean6s.e.m.) in Parkinson
disease cells (n5108 cells from three
independent platings of two patient and
paired control lines). (C,D) Confocal
images of LAMP1 staining in fixed
fibroblasts. Nuclei (stained with DAPI) are
shown in blue. (E) Pooled data quantifying
LAMP1 intensity (left) or the proportion of
cells displaying perinuclear lysosome
clustering (right). Data (mean6s.e.m.) are
from 969 healthy control and 1181 LRRK2-
PD cells from 21 independent platings of a
single patient and paired control line.
(F) Representative electron micrographs
of endolysosomes from a healthy (left) and
LRRK2-PD (right) fibroblast. L, lysosome.
Scale bars: 200 nm. (G) Pooled data
quantifying lysosome area (left) and
density (right). Data (mean6s.e.m.) are
from 100 lysosomes. (H,I) LAMP1 staining
in LRRK2-PD fibroblasts treated for three
days with the LRRK2 kinase inhibitors
LRRK2-In1 (100 nM, H) or GSK2578215A
(32 nM, I). (J) Pooled data quantifying
LAMP1 intensity for the cells shown in H
and I (mean6s.e.m., n5136–335 cells
from five independent platings of two
patient and paired control lines).
***P,0.001.
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morphology was normalised in LRRK2-PD fibroblasts
transfected with a siRNA against TPC2. Quantitative PCR
confirmed selective knockdown of TPC2 transcripts in siRNA-
treated cells (Fig. 2F). Intriguingly, we noted little effect of TPC1
silencing on lysosomal morphology in LRRK2-PD fibroblasts
(Fig. 2D,E) despite demonstrable knockdown at both the
transcript (Fig. 2F) and protein (supplementary material Fig.
S2B) level.
Exaggerated perinuclear clustering of lysosomes in LRRK2-
PD cells (Fig. 1) is consistent with the actions of both TPC2 (Lin-
Moshier et al., 2014) and Rab7 (Bucci et al., 2000; Hutagalung
and Novick, 2011). We therefore tested the effects of inhibiting
Rab7 GTPase activity (Agola et al., 2012) on lysosomal
morphology and distribution in LRRK2-PD fibroblasts.
Importantly, lysosomal defects in LRRK2-PD cells were
corrected upon Rab7 inhibition (Fig. 2G–K; supplementary
material Fig. S3). This reversal was concentration dependent
(Fig. 2L). Levels of endogenous VPS35, a component of the
retromer complex (MacLeod et al., 2013), were unchanged in our
LRRK2-PD fibroblasts compared to controls (supplementary
material Fig. S2A). Taken together, data presented here reveal a
specific role for TPC2 and a newly identified interactor (Rab 7) in
regulating lysosomal morphology in LRRK2-PD cells.
Lysosomal morphology defects are dependent on NAADP
and PtdIns(3,5)P2
Much evidence has accumulated identifying TPCs as the long-
sought endolysosomal targets for NAADP (Brailoiu et al., 2009;
Calcraft et al., 2009; Hooper and Patel, 2012; Zong et al., 2009).
Notably, NAADP-induced Ca2+ release is inhibited when TPCs
are silenced or genetically deleted (Brailoiu et al., 2009; Calcraft
et al., 2009; Davis et al., 2012; Dionisio et al., 2011; Grimm et al.,
Fig. 2. TPC2 but not TPC1 mediates
lysosomal morphology disturbances.
(A–D) LAMP1 staining in fibroblasts from a
healthy control (CTRL) (A) and a Parkinson
disease patient (PD) (B–D) treated with either a
control siRNA (Scr. siRNA) (A,B) or siRNA to
TPC2 (C) or TPC1 (D). Scale bars: 5 mm.
(E) Pooled data quantifying LAMP1 intensity for
the cells shown in A–D (mean6s.e.m., n5381–
532 cells from six independent knockdowns
from two patient and paired control lines).
(F) Quantitative PCR analysis of TPC2 (left) and
TPC1 (right) levels in cells treated with the
indicated TPC siRNA. Data are from two
patients and are normalised to TPC levels in
cells treated with scrambled control siRNA.
(G–I) Lysosomal morphology in control
fibroblasts (G) or LRRK2-PD fibroblasts treated
without (H) or with (I) the Rab7 GTPase
inhibitor CID 1067700 (1 mM, 3 days).
(J,K) Pooled data quantifying LAMP1 intensity
(J) or the proportion of cells displaying
perinuclear lysosome clustering (K) for the cells
shown in G–I (mean6s.e.m., n5237–281 cells
from five independent platings of three patient
and paired control lines). ***P,0.001.
(L) Concentration–effect relationship
(mean6s.e.m., n5130–281 cells from five
independent platings of three patient lines) for
the Rab7 GTPase inhibitor on lysosome
clustering in LRRK2-PD fibroblasts.
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2014; Lu et al., 2013). However, this view has been challenged by
evidence suggesting that TPCs are not NAADP-sensitive channels
but are instead Na+ channels gated by phosphatidylinositol 3,5-
bisphosphate [PtdIns(3,5)P2] (Wang et al., 2012). We therefore
examined the effects of antagonising the action of NAADP and
PtdIns(3,5)P2 on lysosomal morphology in LRRK2-PD fibroblasts
(Fig. 3A). Potential NAADP involvement was assessed using the
NAADP antagonist Ned-19 (Naylor et al., 2009) and its novel
analogue Ned-K (see Materials and Methods). As shown in
Fig. 3B–F and supplementary material Fig. S3, lysosomal
morphology in LRRK2-PD fibroblasts treated with either Ned-19
or Ned-K was similar to control cells. Reversal of defective
lysosomal morphology by both compounds was dependent on
concentration (Fig. 3G). Ned-19 and Ned-K thus mimicked the
effects of TPC2 silencing (Fig. 2). We used the PIKfyve inhibitor,
YM-201636 to deplete PtdIns(3,5)P2 levels (Jefferies et al., 2008).
Acute treatment with the drug was also sufficient to reverse
lysosomal morphology defects (Fig. 3H–J), again similar to the
effects of silencing TPC2. Collectively, these molecular and
pharmacological data suggest that TPCs are regulated by both
NAADP and PtdIns(3,5)P2, findings consistent with recent reports
(Grimm et al., 2014; Jha et al., 2014). These data also highlight the
utility of mechanistically distinct small molecule inhibitors in
correcting lysosomal pathology.
Pathogenic LRRK2 disrupts local and global Ca2+ signalling
TPCs are ostensibly Ca2+-permeable, and constitutive Ca2+
release events within the endolysosomal system are known to
regulate organelle fusion (Pryor et al., 2000). To probe the role of
Ca2+ in lysosomal disturbances, we buffered Ca2+ levels using
cell-permeable forms of either BAPTA or EGTA (Morgan et al.,
2013). As shown in Fig. 4A–C and summarised in Fig. 4E,
lysosomal morphology in LRRK2-PD fibroblasts acutely treated
with BAPTA-AM were similar to control cells, suggesting that
the morphological defects are dependent on Ca2+. However,
treatment with EGTA-AM (a slower Ca2+ chelator) proved
ineffectual (Fig. 4D,E). These data indicate that disrupted
lysosomal morphology is likely due to dysregulated local Ca2+
signalling. This might promote Ca2+-dependent fusion of
lysosomes (Pryor et al., 2000) and thus enlargement. Indeed,
we often encountered large hourglass-shaped organelles
delineated by a continuous membrane consistent with a fusion
defect in Parkinson disease fibroblasts (supplementary material
Fig. S4).
Fig. 3. Lysosomal defects are NAADP- and
PtdIns(3,5)P2-dependent. (A) Schematic of
the TPC (yellow) showing proposed ion
permeability (Ca2+ and Na+; grey arrows) and
activating ligands (NAADP and PtdIns(3,5)P2;
green arrows). Drugs used are highlighted in
italics and their loci of action is shown in red.
(B–E) LAMP1 staining in fibroblasts from a
healthy control (CTRL) (B) and a Parkinson
disease (PD) patient (C–E) treated for 3 days
with either DMSO (B,C) or the NAADP
antagonists, Ned-19 (100 mM, D) and Ned-K
(100 mM, E). Scale bars: 5 mm. (F) Pooled
data quantifying LAMP1 intensity for the cells
shown in B–E (mean6s.e.m., n592–322 cells
from six independent platings of three patient
and paired controls). (G) Concentration–effect
relationships (mean6s.e.m., n540–206 cells
from six independent platings of three patient
lines) for Ned-19 (black circles) and Ned-K
(white circles) on lysosomal morphology in
LRRK2-PD fibroblasts. (H,I) LAMP1 staining in
LRRK2-PD fibroblasts treated without (H) or
with the PIKfyve inhibitor YM-201636 (1 mM,
2 h) (I). (J) Pooled data quantifying LAMP1
intensity for the cells shown in H and I
(mean6s.e.m., n573–292 cells from two
independent platings of two patient and paired
control lines). ***P,0.001.
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To further probe the role of Ca2+ in pathogenic LRRK2 action,
we measured global cytosolic Ca2+ levels in response to NAADP
stimulation. As shown in Fig. 4F, microinjection of fibroblasts with
NAADP, but not vehicle, evoked Ca2+ signals. NAADP responses
were significantly larger in LRRK2-PD fibroblasts than in healthy
controls (Fig. 4G,H). These signals are likely the global correlate of
enhanced TPC activity that underlies the trafficking defect. Thus,
both local (constitutive) and global (NAADP-regulated) Ca2+
signals are disrupted upon LRRK2 mutation.
In summary, we identify trafficking defects in LRRK2-PD
fibroblasts that result from interplay between TPC2, its regulatory
interactors and ligands, and the associated Ca2+ fluxes. TPC2 and
LRRK2 co-immunoprecipitate (Go´mez-Suaga et al., 2012)
raising the possibility that TPC2 is phosphorylated by LRRK2.
Given that similar morphological changes within the endo-
lysosomal system have been observed during normal ageing and
in other neurodegenerative conditions (Nixon et al., 2008), we
suggest that aberrant TPC signalling might have broader
relevance to declining cellular function.
MATERIALS AND METHODS
Cell culture
Fibroblast cultures from four Parkinson disease patients carrying the G2019S
mutation in LRRK2 and four healthy donors (each pair age-matched within 2
years; age range 48–71) were established as described previously
(Papkovskaia et al., 2012). The study was approved by the Hampstead
Research Ethics Committee. All individuals provided written informed
consent for the provision of samples. Cells were maintained in DMEM
supplemented with 10% (v/v) fetal bovine serum, 100 units/ml penicillin and
100 mg/ml streptomycin (all from Invitrogen) at 37 C˚ in a humidified
atmosphere with 5% CO2. Cells were passaged by scraping and plated onto
glass coverslips (for confocal microscopy and Ca2+ imaging), thermanox
coverslips (for electron microscopy) or directly onto tissue culture plates or
flasks (for western blotting) before experimentation. Cultures were used
between passage 6–15 and at 4–7 days post plating. Control and LRRK2-PD
cultures were analysed in parallel and differed by no more than two passages.
Drug treatment
All drugs used in this study were dissolved in DMSO, diluted into culture
medium and the medium sterile filtered prior to use. The LRRK2 kinase
inhibitors LRRK2-In1 and GSK2578215A were from Merck and R&D
Systems, respectively. The Rab7 GTPase inhibitor, CID 1067700 (Agola
et al., 2012) was from EMD Millipore. The NAADP antagonist trans-
Ned-19 was synthesised as described previously (Naylor et al., 2009).
Ned-K is an analogue of Ned-19 in which the fluoride has been replaced
with a cyano group. Its synthesis will be described elsewhere. Both Ned-
19 and Ned-K were kind gifts from A. Ganesan (School of Pharmacy,
University of East Anglia, UK), Raj Gossain (School of Chemistry,
University of Southampton, UK) and Sean M. Davidson (Hatter Institute,
UCL, UK). The PIKfyve inhibitor, YM-201636 was from Cambridge
Bioscience. BAPTA-AM and EGTA-AM were from Sigma.
siRNA
Fibroblasts were transfected with siRNAs using LipofectamineHRNAiMAX
for 24 h, re-transfected for an additional 24 h and cultured for a final 24 h in
the absence of siRNA prior to experimentation. A control siRNA duplex
(Allstars Negative Control siRNA) and duplexes targeting human TPC1 (59-
CGAGCTGTATTTCATCATGAA-39) (Brailoiu et al., 2009) and TPC2 (59-
CAGGTGGGACCTCTGCATTGA-39) were purchased from Qiagen.
Lysotracker labelling
Fibroblasts were washed three times in HEPES-buffered saline (HBS)
comprising (in mM) 1.25 KH2PO4, 2 CaCl2, 2 MgSO4, 3 KCl, 156 NaCl,
10 glucose and 10 HEPES (pH 7.4; all from Sigma) and were then
Fig. 4. Pathogenic LRRK2 disrupts local
and global Ca2+ signalling. (A–D) LAMP1
staining in fibroblasts from a healthy control
(CTRL) (A) and a Parkinson disease patient
(PD) (B–D) treated for 2 h with either DMSO
(A,B) or 10 mM acetoxymethyl (AM) esters of
the Ca2+ chelators BAPTA (C) or EGTA (D).
Scale bars: 5 mm. (E) Pooled data quantifying
LAMP1 intensity for the cells shown in A–D
(mean6s.e.m., n5150–307 cells from six
independent platings of two patient and paired
controls). ***P,0.001. (F,G) Cytosolic Ca2+
responses of individual Fura-2-loaded healthy
(F) or Parkinson disease (G) fibroblasts
microinjected with either vehicle (blue traces)
or NAADP (20 mM pipette; black traces).
(H) Pooled data (n56) quantifying the change
in ratio upon microinjection of NAADP (left) or
vehicle (right).
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incubated with 100 nM LysotrackerH red (Invitrogen) for 20 min. Cells
were washed again three times in HBS, and mounted in an imaging
chamber (Biosciences Tools) prior to confocal microscopy.
Immunocytochemistry
Fibroblasts were fixed for 10 min with 4% (w/v) paraformaldehyde,
washed three times in phosphate-buffered saline (PBS) and then
permeabilised for 10 min with 40 mM b-escin. Cells were washed
again (three times in PBS), and blocked for 1 h with PBS supplemented
with 1% (w/v) BSA and 10% (v/v) FBS. Fibroblasts were sequentially
incubated for 1 h at 37 C˚ with a primary anti-LAMP1 antibody (mouse,
Developmental Studies Hybridoma Bank H4A3 clone supernatant; 1:10
dilution) and a secondary antibody conjugated to Alexa Fluor 647
(mouse, Invitrogen, 1:100 dilution) in blocking solution. Nuclei were
labelled with 1 mg/ml DAPI (5 min). Cells were washed three times in
PBS containing 0.1% (v/v) TweenH 20 in between incubations and
mounted onto microscope slides with DABCO.
Microscopy
Confocal images were captured using an LSM510 confocal scanner
(Zeiss) attached to a Zeiss Axiovert 200M inverted microscope fitted
with a 636 Plan Apochromat water-immersion objective. DAPI,
LysotrackerH Red and Alexa Fluor 647 were excited at 364 nm,
543 nm and 633 nm, and emitted fluorescence captured using 385 nm
long pass, 585–615 nm band-pass or 655–719 nm band-pass filters,
respectively. Images for control and LRRK2-PD cells together with the
various treatments were captured under identical acquisition settings in
order to allow comparison of fluorescent intensity. Electron microscopy
was performed as described previously (Tomas et al., 2004) using a JEOL
1010 transmission electron microscope.
Quantitative PCR
Total RNA was isolated using TRIzolH (Invitrogen) according to the
manufacturer’s procedures. cDNA was synthesised using SuperScriptH III
reverse transcriptase (Invitrogen). Samples were denatured for 2 min at
94 C˚ followed by 40 cycles of denaturation (15 s, 94 C˚), annealing (30 s,
60 C˚) and extension (30 s, 72 C˚) using SYBRH Green PCR mix
(Invitrogen) and oligonucleotide primers designed for human TPC1 and
TPC2 as previously described (Brailoiu et al., 2009). Expression levels were
normalised to the expression of GAPDH following parallel amplification.
Western blotting
Fibroblasts were harvested by scraping and lysed in Ripa buffer
containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 0.5% sodium
deoxycholic acid, 0.1% sodium dodecyl sulphate and 1% Triton X-100 in
the presence of EDTA-free protease inhibitor (Roche) and HaltTM
phosphatase inhibitor cocktail (Thermo Scientific) for 30 min on ice.
Samples were centrifuged at 15,000 g at 4 C˚ for 15 min and the resulting
supernatants stored at 220 C˚ until required. Samples (10–30 mg) were
reduced with dithiothreitol (100 mM), separated on NuPAGEH 4–12%
Bis-Tris gels (Invitrogen) and transferred onto PVDF filters (Biorad)
according to standard procedures. The filters were then blocked with 5%
(w/v) dried skimmed milk in Tris-buffered saline (25 mM Tris-HCl,
137 mM NaCl and 2.7 mM KCl, pH 7.4) containing 0.1% (v/v) TweenH
20 (TBS-T) for either 1 h at room temperature or overnight at 4 C˚. Blots
were sequentially incubated with primary and secondary antibodies in
TBS-T supplemented with 2.5% (w/v) dried skimmed milk. After each
step, the filters were washed with TBS-T (3630 min). The resulting blots
were developed using the ECLTM Prime Western Blot Detection System
(GE Healthcare) according to the manufacturer’s instructions. The
primary antibodies used were anti-LAMP1 (mouse, Santa Cruz
Biotechnology; 1:500, overnight 4 C˚), anti-TPC1 (rabbit, Abcam,
1:200, 1 h room temperature), anti-VPS35 (rabbit, Abcam, 1:1000,
overnight 4 C˚) and anti-actin (goat, Invitrogen, 1:500, 1 h room
temperature) antibodies. The secondary antibodies used were anti-
mouse-IgG (Santa Cruz Biotechnology), anti-rabbit-IgG (Bio-Rad) or
anti-goat-IgG (Santa Cruz Biotechnology) conjugated to horseradish
peroxidase (1:2000, 1 h room temperature).
Ca2+ imaging and microinjection
Cytosolic Ca2+ concentration measurements using Fura-2 and microinjection
were performed as described previously (Deliu et al., 2012).
Data analysis
Images were analysed using ImageJ software. For LysotrackerH red and
LAMP1 intensity measurements, background was subtracted from the
images and mean grey intensity per cell measured within user defined
regions-of-interest (comprising the whole lysosome population).
Statistical analyses were performed using IBM SPSS statistics 22
software. Independent Student’s t-tests or one-way ANOVA followed by
Games–Howell post hoc tests were applied to calculate statistical
significance. Values are presented as mean6s.e.m. For ANOVA analysis,
threshold of significance was maintained at P,0.016 to correct for
multiple testing error.
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